The James Altucher Show

A Note from James:
I’m doing a big experiment in my life.
I recently started taking a GLP-1—tirzepatide, one of the so-called weight-loss drugs. But I didn’t start taking it specifically for weight loss. I had some blood work done for the first time in a long time, and there was a small indication that I might be pre-diabetic. My doctor suggested trying tirzepatide, and I wanted to understand what I was getting into.
The first person I wanted to talk to was Charles Duhigg, author of The Power of Habit and Supercommunicators. Charles has been taking a GLP-1 for about two years, and he says it has changed his life. He has lost around 45 pounds, but what interested me most was not just the weight loss. It was the habit change.
Charles explains that GLP-1s can quiet what people now call “food noise”—the constant background pull toward eating even when you are not actually hungry. When that noise quiets down, something interesting happens: you get a window where your old habits become more malleable.
That is the key idea of this conversation. The drug may help you eat less, but the bigger opportunity is that it gives you a chance to build new routines around food, exercise, alcohol, sleep, and identity. And if you build those habits while the window is open, those habits may continue even after you stop taking the medication.
We talk about food noise, cravings, the habit loop, keystone habits, stated versus revealed preferences, placebo effects, alcohol, sleep, exercise, blood sugar, identity, and whether GLP-1s are a lifelong drug or a tool for changing who you become.

Episode Description:
James is at the beginning of a GLP-1 experiment. Charles Duhigg is two years in.
In this conversation, Charles explains what he has learned from taking tirzepatide and from studying GLP-1s through the lens of habit formation. He describes the first phase of public understanding around these medications as weight loss. Phase two, he argues, is about behavior change.
The central concept is “food noise.” Charles describes it as the background craving that turns a basket of fries into an almost automatic behavior. You may not even notice the noise until it goes away. Once it quiets, the cue that normally triggers the habit loop weakens. That creates a temporary window where new habits can be built.
James and Charles use the GLP-1 experience to revisit the basic habit loop: cue, routine, reward. They talk about why habits feel automatic, why willpower is often the wrong tool, and why successful behavior change depends on identifying the cue and replacing the routine while still satisfying the underlying reward.
Charles also introduces the idea of GLP-1s as a catalyst for keystone habits. Eating less can make exercise easier. Drinking less can improve sleep. Better sleep can improve focus. Focus can improve work. One changed habit can set off a chain reaction.
The conversation then becomes more philosophical: Who are we if one part of the brain says “I want to be healthy,” while another part of the brain keeps revealing different preferences through action? Charles explains the difference between stated preferences and revealed preferences, and how repeated behavior can shift identity.
This is not a conversation about taking GLP-1s casually. It is a conversation about using a medical intervention deliberately, under appropriate medical guidance, as a chance to change the patterns that shape daily life.

Editorial Note:
This episode discusses prescription medications, including tirzepatide and semaglutide, as well as personal experiences with GLP-1 drugs. It should not be treated as medical advice.
GLP-1 medications can have side effects and risks, including gastrointestinal symptoms, dosing concerns, and contraindications for some patients. They should be used only under the supervision of a qualified medical professional. Any decision to start, stop, adjust, or combine medications should be made with a clinician.
James and Charles also discuss personal experience, habit change, appetite, alcohol cravings, and identity. Individual responses to these medications vary.

What You’ll Learn:
Why Charles believes GLP-1s are entering “phase two”: not just weight loss, but habit change.
What “food noise” feels like—and why people often do not notice it until it disappears.
How GLP-1s may create a temporary “habit window” where old routines become easier to change.
Why the habit loop—cue, routine, reward—matters when trying to change eating behavior.
Why people often regain weight after stopping GLP-1s if they have not built new habits.
How keystone habits can create a chain reaction across food, exercise, alcohol, sleep, and focus.
Why micro habits may work better than a full lifestyle overhaul.
How stated preferences and revealed preferences shape identity.
Why eating less can make exercise easier, and why exercise can reinforce healthier choices.
Why tracking behavior may be essential while taking a GLP-1.
How placebo, alter egos, and rituals may influence identity and performance.
Why the goal is not just losing weight, but becoming the kind of person whose habits support health.

Timestamped Chapters:

[03:36] James Begins His GLP-1 Experiment
James explains his early experience, including confusion between medication side effects and a bout of COVID.
[04:16] Charles’s Two-Year Experience
Charles describes taking tirzepatide, losing roughly 45 pounds, and why the biggest changes came months into the process.
[05:38] Phase One vs. Phase Two of GLP-1s
Phase one was about appetite and weight loss. Phase two, Charles argues, is about habits that can last.
[06:42] The Habit Window
How GLP-1s can quiet food noise and create a period where eating habits become more malleable.
[07:21] COVID, Side Effects, and Early Signals
James explains why his first few weeks were hard to interpret and why he is still figuring out what the medication is doing.
[09:00] What Food Noise Actually Feels Like
Charles uses the example of a basket of fries to explain cravings, cues, and automatic eating.
[09:55] The Habit Loop: Cue, Routine, Reward
Charles revisits the framework from The Power of Habit and applies it directly to food cravings.
[10:42] How GLP-1s Interrupt the Cue
The fries are still there, but the craving does not activate in the same way.
[11:40] What GLP-1s Do in the Body and Brain
Charles explains what researchers know about gastric emptying, glucagon-like peptides, and what remains uncertain about the brain.
[12:43] What Happens When You Stop
Why the medication alone may not be enough if old habits return after discontinuation.
[13:36] Pleasure, Food, Alcohol, and Anhedonia
Charles discusses reduced pleasure from food and alcohol, while separating clinical findings from broader claims about losing joy in life.
[15:54] Why Charles Stayed With It
Early changes were not dramatic weight loss, but a growing feeling that eating became more of a choice.
[16:40] Eating as a Keystone Habit
How changing food behavior can trigger changes in exercise, alcohol, sleep, focus, and work.
[19:31] Why Structure Matters
Charles explains why tracking and guided habit systems can help people see patterns they might miss on their own.
[20:32] What Changes Physically Over Time
Slower stomach emptying, feeling full longer, more stable blood sugar, and gradual changes in appetite.
[21:43] Stated Preferences vs. Revealed Preferences
Why one part of the brain says “I want to change,” while another part watches what you actually do.
[23:22] Identity Change and Habit Formation
How repeated behavior can teach the brain, “I am the kind of person who eats this way” or “I am the kind of person who exercises.”
[24:16] Placebo, Belief, and Becoming the Person You Want to Be
James and Charles explore whether placebo effects may work partly by changing identity.
[28:07] Alter Egos, Athletes, and Rituals
The conversation turns to Kobe Bryant, Michael Phelps, and how pre-performance routines can cue a desired identity.
[29:15] Start With Micro Habits
Charles explains why small behavior changes can compound more effectively than trying to overhaul an entire life at once.
[30:40] Charles’s First Micro Habits
Drinking less, eating fewer fries, stopping when full, and choosing healthier meals without relying on willpower.
[31:24] Feeling Full for the First Time
Charles describes the surprising experience of leaving food unfinished because his body had had enough.
[33:03] Why the Stomach Shrinks
The medication does not shrink the stomach directly; eating less over time changes how much food the body expects.
[33:21] Why Slower Stomach Emptying Helps
James asks why a weight-loss drug would slow digestion instead of speeding metabolism.
[35:00] The Cumulative Effect
Why the most visible changes often appear after several months, once habits, body size, and identity begin reinforcing each other.
[37:03] Is a GLP-1 a Lifelong Drug?
Charles explains what research and personal experience suggest about stopping, restarting, and maintaining results.
[38:56] James’s Health Motivation
James explains that his motivation is not primarily weight loss, but a desire to respond to possible pre-diabetic markers.
[39:36] Why Attitude Is Not Enough
Charles argues that wanting to be healthy helps, but habit change still requires structure.
[40:02] What Changed at Home
Charles explains how his family’s food did not need to change, even though his own choices and portions did.
[41:02] Weight, Body Composition, and Pre-Diabetes
Why blood sugar, insulin resistance, fat, and muscle matter more than the scale alone.
[42:38] Semaglutide, Tirzepatide, and What Comes Next
James and Charles compare different GLP-1 medications and discuss how newer drugs may work through multiple receptors.
[44:27] Will Charles Stop Taking It?
Charles explains why he may eventually discontinue the medication, but values having more choice over weight and behavior.
[45:24] Blood Work, Snoring, and Health Markers
Charles describes improvements in lab results, cholesterol, snoring, and overall health.
[46:31] Who Are We, Really?
James and Charles talk about identity, brain chemistry, sugar, alcohol, cravings, and the substances that shape behavior.
[48:32] Choosing the Person You Want to Become
Charles explains how better self-awareness can help people change habits deliberately rather than being pulled by cravings.
[49:00] Tracking the Experiment
Charles advises James to track food, feelings, and behavior so he can notice changes that might otherwise be invisible.

Additional Resources:
Charles Duhigg Official Website
The Power of Habit by Charles Duhigg
Supercommunicators by Charles Duhigg
Noom’s GLP-1 Companion / Habit Formation Announcement
FDA: Zepbound Approval for Chronic Weight Management
FDA: Concerns With Unapproved GLP-1 Drugs Used for Weight Loss
BMJ: Weight Regain After Stopping Weight-Loss Medication
Todd Herman — The Alter Ego Effect

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

A Note from James:
I’ve done several hundred podcasts, but if people asked me who were the one or two people I most wanted to have on the show, Garry Kasparov would be at the top of the list. He was World Chess Champion for twenty years, and I’ve followed his career since the early ’80s.
His book, Deep Thinking, tells the story of his matches against Deep Blue, but it’s really about what may be the most important relationship of this century: humans and machines.

Episode Description:
In this From the Archive episode, James talks with Garry Kasparov in his first appearance on the show. Kasparov looks back at the matches that shaped him: his comeback from a 5–0 deficit against Anatoly Karpov, the psychological side of elite competition, and his historic showdown with IBM’s Deep Blue.
They also talk about why a computer beating a world champion did not settle the question of intelligence, how technology changes the kind of work people do, and why fear of making a mistake often causes the mistake itself. Kasparov shares what chess taught him about preparation, adaptability, mentorship, and making decisions when there is no obvious right move.
This conversation was recorded in 2017; the political discussion reflects that moment in time.

What You’ll Learn:
Why adaptability—not strength or intelligence alone—is what helps people survive major change.
How Kasparov used a 5–0 deficit against Karpov to build confidence, patience, and resilience.
Why fear can paralyze decision-making when the stakes are high.
How to think about AI and automation as forces that create new possibilities as they eliminate old roles.
Why mentors, pattern recognition, and disciplined practice matter in chess and every other field.

Timestamped Chapters:
[02:05] Fear, choices, and the danger of paralysis
[03:06] James meets Garry Kasparov
[05:11] Deep Thinking and the question of machine intelligence
[06:35] Growing up with chess in the Soviet Union
[10:11] Botvinnik, preparation, and training through distraction
[12:30] Facing Karpov and falling behind 5–0
[20:20] The value of adapting under pressure
[23:53] Psychology and what separates champions
[26:16] Kasparov’s playing style and coaching Magnus Carlsen
[30:18] Why Deep Blue forced Kasparov to change his game
[31:25] AI, automation, and the future of work
[38:38] What happened in the Deep Blue matches
[42:32] Chess, Go, and the limits of human accuracy
[46:08] Fear, risk, and making better decisions
[48:56] The Kasparov Chess Foundation and education
[57:08] Russia, Putin, and political opposition in 2017
[63:46] How to adapt to technological change

Additional Resources:
Deep Thinking: Where Machine Intelligence Ends and Human Creativity Begins
Winter Is Coming: Why Vladimir Putin and the Enemies of the Free World Must Be Stopped
IBM’s history of Deep Blue
Kasparov Chess Foundation

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

A Note from James:
This is a very special episode for me.
There have only been a few times in the history of this podcast when I’ve had the chance to sit down with one of my heroes. This is one of those times.
Frank Miller is one of the most important storytellers of my life. When I first picked up Batman: The Dark Knight Returns in 1986, it completely changed what I thought comics could be. This wasn’t just another Batman story. It was a revolution. Frank took Batman out of the colorful, campy world I grew up with and turned him into something darker, mythic, terrifying, and psychologically real.
There is a comic book industry before The Dark Knight Returns, and there is a comic book industry after The Dark Knight Returns. Every Batman movie since then carries Frank’s fingerprints in some way. But it wasn’t just Batman. Frank changed Daredevil. He created Ronin. He created Sin City. He showed that comics could handle adult stories, painful arcs, crime, tragedy, mythology, obsession, and moral ambiguity.
But what matters most to me is that Frank is a master storyteller. And I love storytelling. Whether it’s books, podcasts, articles, comics, or just how we make sense of our lives, story is everything.
So getting to sit down with Frank Miller and talk about Batman, myth, creativity, mentorship, discipline, and his new book, Push the Wall: My Life, Writing, Drawing, and the Art of Storytelling, was a dream come true.
This was my first in-person podcast in years. Jay drove up from Atlanta. I flew into the city. And yes, I brought my copy of The Dark Knight Returns for Frank to sign.

Episode Description:
Frank Miller didn’t just write and draw some of the most influential comics of the modern era. He changed the grammar of comics.
In this conversation, James sits down with Miller to talk about Batman: The Dark Knight Returns, Daredevil, Ronin, Sin City, and Miller’s new book, Push the Wall. The conversation begins with Batman, but quickly becomes a larger discussion about how characters become myths.
For Miller, Batman was never just a rich detective in a costume. The material was already there from the beginning: a child witnessing the murder of his parents, growing up without powers, building himself into a force through discipline, intelligence, and obsession. Miller’s goal was to pull that core truth out and make Batman stand beside older pulp and mythic figures like Zorro, The Shadow, and the hard-edged heroes of crime cinema.
James and Frank also talk about how myths are built around simple central values. Superman is hope. Batman is justice, vengeance, effort, and fear. The art is not in making those ideas complicated. The art is in placing them inside a human context so they feel emotionally true.
The discussion moves into the craft of comics itself: page layouts, panel borders, visual rhythm, and how the pictures carry most of the story. Miller reflects on the influence of Jack Kirby, Neal Adams, Denny O’Neil, Japanese samurai films, martial arts movies, Greek tragedy, Jean Giraud/Moebius, Lone Wolf and Cub, and the creative power of combining worlds that do not obviously belong together.
They also talk about mentorship. Miller describes calling Neal Adams from the phone book, bringing him drawings, and enduring brutally honest criticism. That toughness, he says, was part of the training. To survive as an artist, you need egoism without egotism: enough belief to keep coming back, but enough humility to keep learning.
The episode closes with practical advice for young artists today: go to conventions, build the strongest portfolio you can, seek out hard criticism, don’t chase only the biggest titles, protect your original ideas, and look for “losers” you can make great.

What You’ll Learn:
Why Frank Miller wanted Batman to become a myth, not just another superhero.
How The Dark Knight Returns helped move comics toward darker, more adult storytelling.
Why Batman’s lack of superpowers is exactly what makes him compelling.
How mythic characters are built around simple core themes like hope, vengeance, justice, or discipline.
Why comics are not just written stories with pictures, but a visual storytelling machine.
How Miller learned from Jack Kirby, Neal Adams, Denny O’Neil, samurai films, noir, Greek tragedy, and European comics.
Why creativity often comes from combining unrelated influences.
What Miller means by “egoism, but not egotism.”
Why young artists should seek out hard lessons instead of easy praise.
How to enter comics today without giving away original work too early.
Why determination, stamina, and a lack of Plan B shaped Miller’s career.
What Miller is working on next, including a new Western-style Sin City story.

Timestamped Chapters:
[03:41] Meeting Frank Miller
James begins by holding up Batman: The Dark Knight Returns and asking what it means to be known through one defining work.
[04:00] Before and After The Dark Knight Returns
Why James sees Miller’s Batman as a dividing line in comic book history.
[05:07] Turning Batman Into a Psychological Condition
James asks how Miller transformed Batman from a campy hero into something darker, mythic, and terrifying.
[05:49] Batman as Myth
Frank explains that his first impulse was to make Batman stand with figures like The Shadow, Zorro, and the hard-edged heroes of crime cinema.
[06:37] Pulling Comics Out of Childhood
Miller describes his desire to push comics into adolescence and beyond the conventions of disposable monthly stories.
[06:59] The Origin Was Always There
Why Batman’s trauma, lack of powers, and self-made discipline were already embedded in the character from the beginning.
[07:50] Superman Descends, Batman Rises
Frank contrasts Superman as a figure of light with Batman as something that comes up from the darkness.
[08:44] What Makes a Character Mythic?
Miller explains that great characters usually have a simple central theme: hope, justice, vengeance, effort, or fear.
[10:30] King Arthur, Luke Skywalker, and the Power of Objects
The conversation turns to swords, lightsabers, utility belts, and how mythic symbols carry stories across generations.
[11:54] Breaking the Page
James and Frank discuss how Kirby, Neal Adams, and others shattered conventional panel layouts before Miller pushed those techniques further.
[12:35] A Tradition of Revolution
Frank explains why creativity means breaking a few eggs while still working inside a lineage.
[13:00] When the Page Tells the Story
How panel size, shape, and visual composition can carry emotional meaning without words.
[14:10] What Would Frank Do With Batman Now?
Miller says the point is not to reinvent Batman for novelty’s sake, but to find a good story.
[15:00] Moving Daredevil Into Hell’s Kitchen
James asks how Miller brought his own New York experience into Daredevil’s world.
[15:45] Fear, Editors, and Media Conglomerates
Frank reflects on how creative fear moves through artists, editors, bosses, and corporate structures.
[16:17] Are New Comic Stories Still Possible?
Miller argues that the talent and creative energy are still there, even if it does not always come from predictable places.
[17:40] How Comics Survived Their Own Deaths
Frank traces comic books from the attacks of the 1950s to Marvel, underground comics, and the direct market.
[19:30] What Young Artists Need Today
When James asks what skill matters beyond drawing and storytelling, Miller answers: determination.
[20:01] No Plan B
Frank explains that he never had a concept of failure because comics were what he had wanted to do since his earliest memories.
[20:47] Writing vs. Storytelling
Why, in comics, most of the storytelling happens in the pictures.
[21:00] Neal Adams and the Hard Lessons
Miller remembers calling Neal Adams from the phone book and receiving tough critiques that tested his character.
[22:34] Egoism, Not Egotism
Frank explains the balance an artist needs: enough ego to return after criticism, but not so much that they stop learning.
[22:51] Stealing From the Greats
Why artists must study and learn from earlier practitioners rather than pretending genius arrives fully formed.
[23:47] Batman Is Possessed, Not Obsessed
Frank corrects James’s description of Batman and explains that Batman is filled with an eternal force.
[24:50] Daredevil, Samurai, Crime, and Greek Tragedy
How Miller fused martial arts films, ninja stories, crime movies, and Greek tragedy into his Daredevil run.
[27:01] Stick, Elektra, and the Sensei Archetype
James and Frank trace the mentor-student relationship through Daredevil, samurai stories, and mythic training narratives.
[27:47] Lone Wolf and Cub, Moebius, and Ronin
How Forbidden Planet exposed Miller to Japanese and European comics, leading to the hybrid world of Ronin.
[28:35] The Power of Intersections
Why combining Westerns, samurai stories, science fiction, noir, and mythology can create something new.
[30:08] Discipline vs. Chaos
James identifies a recurring theme in Miller’s work: taking chaos and molding it into purpose.
[30:40] Batman Becomes the Father
Frank explains the final image of The Dark Knight Returns: the orphan becoming the father.
[31:24] Why So Many Heroes Are Orphans
Miller says the lone child against the elements is at the heart of heroic storytelling.
[32:36] Guilt, Control, and Batman’s Unhealed Wound
James and Frank discuss whether Batman is driven by guilt or by the need to take control after childhood trauma.
[33:43] Pushing Batman to the Extreme
Why Miller made the Batmobile a tank and amplified the character’s core qualities.
[33:50] How Frank Would Start Today
Miller advises young artists to attend conventions, show their work, use the internet, and seek honest feedback.
[34:36] Seek Hard Criticism
Why young creators should avoid people who only make them feel good.
[34:59] Don’t Chase the Biggest Titles
Miller advises artists to look for overlooked characters—or better yet, create something themselves.
[35:21] Find a Loser and Do It Right
A practical creative strategy: identify something bad, understand why it fails, and build the better version.
[35:41] Gatekeepers and New Avenues
Frank weighs the traditional obstacles against new channels for artists to get discovered.
[36:27] Protect Your Original Ideas
Why young artists should be careful about handing over original material too early.
[37:00] Humility, Listening, and Surviving the Business
Miller adds that determination must be paired with humility and a willingness to learn how the industry works.
[37:58] Batman at 55—and What Comes Next
James reflects on Batman’s age in The Dark Knight Returns, and Frank jokes that next time Batman may be 80.
[38:36] A New Western Sin City
Frank talks about working on a new Sin City story with a Western angle.
[38:52] Push the Wall and the Art of Creativity
James closes by describing Miller’s new book as a guide to creativity and inspiration.
[39:20] A Dream Interview Comes Full Circle
James thanks Frank, explains the personal significance of the episode, and asks him to sign The Dark Knight Returns.

Additional Resources:
Push the Wall by Frank Miller — Miller’s memoir and guide to writing, drawing, and storytelling.
Batman: The Dark Knight Returns — Miller’s landmark Batman story.
Batman: Year One — Written by Frank Miller with art by David Mazzucchelli.
Frank Miller’s Sin City Deluxe Editions — Dark Horse’s deluxe editions of the noir series.
Lone Wolf and Cub — The samurai manga series Miller discusses as a major influence.
Moebius / Jean Giraud — The European comics artist whose visual world influenced Ronin and modern science-fiction imagery.
Joseph Campbell Foundation — Background on the mythic storytelling ideas referenced in the conversation.
Neal Adams — DC’s remembrance of the artist and mentor Miller discusses.
Jack Kirby Museum — Archive and background on one of Miller’s central comics influences.

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

A Note from James:
I’ve been obsessed with anti-aging and longevity science for a long time. I’ve had many longevity researchers on the podcast, but this episode feels different because something we’ve been discussing for years has now moved into human trials.
David Sinclair first came on the show in 2019, when his book Lifespan was published. He’s a professor of genetics at Harvard Medical School, and that first conversation changed how I lived. I started experimenting with intermittent fasting, paid much more attention to sleep, and began researching many of the supplements and lifestyle changes he discussed.
But the most important idea David talked about wasn’t a supplement. It was the possibility of reversing cellular age using Yamanaka factors—genes that can reset the instructions cells use to function. At the time, nobody knew whether this could be done safely without causing cancer or making cells lose their identities.
Now, a therapy based on three of those factors has entered its first human clinical trial. The initial target is age-related damage to the optic nerve, including open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. The trial is designed primarily to evaluate safety, but researchers will also measure visual function.
David explains how this technology worked in mice and nonhuman primates, why the eye was chosen as the first organ, and how the same approach might eventually be applied to the liver, lungs, joints, skin, and brain.
We also cover the practical questions people always ask him: NMN, NAD, metformin, berberine, testosterone, growth hormone, diet, fasting, sleep, exercise, and what David himself has started—or stopped—taking.
This is still experimental science. Nobody yet knows whether the animal results will translate into meaningful benefits for humans. But for the first time, researchers are beginning to test that question directly.

About Lifespan:
Dr. David Sinclair founded Lifespan to deliver clear, science-backed health insights that help people live longer, more vibrant lives.
He's now building the world's largest community dedicated to extending human longevity well beyond today’s limits. Join early access at lifespan.com.
New episodes of Lifespan with Dr. David Sinclair -- the #1 health and wellness podcast in its first season -- are now available on YouTube, Spotify, Apple Podcasts, and Lifespan.com.

Episode Description:
For years, longevity researchers have looked for ways to slow the biological processes associated with aging. Dr. David Sinclair and his collaborators are now testing a more ambitious possibility: whether damaged human cells can be restored to a younger, more functional state.
The experimental therapy, ER-100, uses controlled expression of three transcription factors—OCT4, SOX2, and KLF4, collectively known as OSK. These are three of the four Yamanaka factors originally used to transform adult cells into pluripotent stem cells.
Turning on all four factors can erase too much of a cell’s identity and has produced tumors and fatal outcomes in animal experiments. Sinclair’s team found that removing one factor, c-MYC, allowed cells to regain younger patterns of gene expression without completely returning to a stem-cell state.
In preclinical studies, OSK restored youthful epigenetic patterns, promoted optic-nerve regeneration, and reversed vision loss in mouse models. Life Biosciences, a company Sinclair co-founded, has now moved the technology into a first-in-human Phase 1 trial involving people with open-angle glaucoma or non-arteritic anterior ischemic optic neuropathy.
David explains how the therapy is delivered directly into the eye and activated using doxycycline, allowing clinicians to control when and for how long the genes are expressed. He also describes the development path that could follow if the treatment proves safe, including therapies targeting the liver and other organs, as well as future medicines that may reproduce similar effects without gene delivery.
The conversation then turns to interventions available today. David distinguishes between promising research and claims that have moved ahead of the evidence, discussing NMN, injected NAD, growth hormone, testosterone, taurine, nattokinase, metformin, berberine, and nootropics.
Throughout the episode, he emphasizes that no supplement has been shown to reproduce the effects researchers are attempting to achieve through partial epigenetic reprogramming—and that many of the most dramatic claims circulating online remain unsupported.

Editorial Note:
ER-100 is an investigational therapy. Authorization to begin a clinical trial does not mean the treatment has been proven safe or effective, nor has it been approved for clinical use.
The Phase 1 study is primarily evaluating safety and tolerability, with additional measurements of visual function. Results from mice and nonhuman primates do not establish that the therapy will restore vision or reverse biological aging in people.
The discussion of supplements, prescription medications, hormones, and lifestyle practices reflects the speakers’ personal views and interpretation of the research. It should not be treated as individualized medical advice. Prescription drugs, hormones, supplements, and experimental longevity treatments should be discussed with an appropriately qualified healthcare professional.

What You’ll Learn:
How partial epigenetic reprogramming differs from completely resetting a cell into a stem cell.
Why researchers selected three Yamanaka factors—OCT4, SOX2, and KLF4—instead of using all four.
What ER-100 is designed to do and why the first human trial focuses on the optic nerve.
How doxycycline acts as an external switch controlling when the therapeutic genes are expressed.
What Phase 1 researchers will measure and what would need to happen before ER-100 could become an approved treatment.
Why the eye provides a useful starting point for testing cellular rejuvenation.
What animal studies suggest about restoring vision, memory, liver function, joints, and skin.
Why delivering rejuvenation therapies throughout the body is more difficult than treating one localized organ.
The difference between oral NMN supplementation and intravenous or subcutaneous NAD.
What current research does—and does not—show about growth hormone, testosterone, taurine, metformin, and berberine.
Why muscle, exercise, sleep, diet, glucose regulation, and inflammation remain important even if rejuvenation therapies eventually succeed.
How Sinclair’s laboratory is searching for pills and small molecules that could mimic epigenetic reprogramming without gene therapy.

Timestamped Chapters:
[04:53] The First Human Trial Begins
David discusses ER-100, FDA authorization, and the treatment of open-angle glaucoma and ischemic optic neuropathy.
[06:52] What Are the Yamanaka Factors?
How reprogramming genes can reset cellular instructions—and why using all four factors can be dangerous.
[08:56] Reversing Vision Loss and Memory Problems in Animals
David describes studies involving the eyes, brain, skin, kidneys, liver, and age-related cognitive decline.
[10:09] Why Four Factors Can Cause Cancer
The difference between restoring youthful function and erasing a cell’s identity completely.
[10:54] The Three-Gene Breakthrough
How Sinclair’s student Yuancheng Lu persisted through years of failure and identified the OSK combination.
[12:03] Pulsing the Genes vs. Leaving Them Activated
Earlier four-factor experiments required intermittent activation, while OSK showed a different safety profile in animal eyes.
[13:36] The Doxycycline Safety Switch
How clinicians may use an antibiotic to activate and deactivate the therapy after it has been delivered.
[14:51] Treating the Cause Instead of the Symptoms
David argues that restoring younger tissue function could allow the body to repair damage associated with age-related disease.
[16:02] Why the Trial Starts With the Eye
Localized delivery reduces systemic exposure and makes visual changes easier to observe and measure.
[16:50] Can the Therapy Reach the Brain and the Rest of the Body?
The challenges of distributing gene-based treatments evenly across organs and through the blood-brain barrier.
[18:25] What the Phase 1 Trial Will Measure
Safety, tolerability, visual function, and the possibility of an accelerated development path.
[20:36] Expanding Beyond Glaucoma
Why each organ may require a different delivery vehicle—and how the liver could become another early target.
[21:38] How Shinya Yamanaka Found the Original Four Factors
The trial-and-error process that turned adult cells into induced pluripotent stem cells.
[22:38] How ER-100 Is Delivered
David explains the OSK genes, the AAV delivery system, doxycycline activation, and why manufacturing is expensive.
[25:21] When Could the Treatment Become Available?
David gives his most optimistic development timeline and discusses parallel programs targeting other organs.
[27:31] NMN, NAD, Sirtuins, and the Information Theory of Aging
How declining NAD levels may affect cellular defenses and the regulation of gene expression.
[31:34] Oral NMN vs. Injected NAD
Why David believes oral supplementation currently has more rigorous evidence than NAD injections.
[32:20] Longevity Misinformation Online
David explains why he is restarting his show and warns against confident recommendations unsupported by research.
[32:41] Growth Hormone and Lifespan
Why growth hormone may improve certain functions but has not been shown to slow aging or extend human life.
[34:05] Testosterone, Muscle Mass, and Healthy Aging
Potential benefits for maintaining muscle—and why testosterone alone should not be considered a longevity treatment.
[36:01] Taurine, Nattokinase, and Changing Your Mind
Why David stopped taking taurine regularly and what prompted his interest in nattokinase.
[37:30] David’s Current Diet and His 86-Year-Old Father
Lower meat and cheese consumption, little alcohol, exercise, supplements, and tracking inflammation through biomarkers.
[39:33] James’s Longevity Routine
Limited processed sugar, intermittent fasting, reduced meat and alcohol, and prioritizing eight hours of sleep.
[40:07] Why Sleep Cleans the Brain
The relationship between sleep, waste removal, protein accumulation, cognition, and dementia risk.
[40:33] Metformin as a Possible Longevity Drug
Why a medication developed for type 2 diabetes remains central to aging research.
[41:41] Berberine and Mitochondrial Function
What clinical studies suggest about glucose regulation and why David sometimes alternates berberine with metformin.
[43:10] Modafinil, Adderall, and Nootropics
Possible short-term benefits for focus weighed against uncertainty about long-term consequences.
[43:43] What Comes After the Eye Trial?
Potential applications involving the liver, lungs, kidneys, joints, brain, and other age-related conditions.
[45:14] Can Rejuvenation Make Skin Look Younger?
David describes unpublished work involving human skin, wound healing, and orally delivered compounds in mice.
[46:17] Beyond Gene Therapy: A Rejuvenation Pill
How AI and chemical screening may help reproduce the effects of early embryonic reprogramming more cheaply and simply.
[47:31] When Could Chemical Reprogramming Reach Humans?
David discusses the preclinical safety work and the uncertainty surrounding future human studies.
[48:11] The Lifespan Community and Foundation
David introduces his new show, longevity community, and support for scientific research.

Additional Resources:
ER-100 Phase 1 Trial — ClinicalTrials.gov
Official registration for the first-in-human study evaluating ER-100 in open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy.
Life Biosciences: FDA Clearance for ER-100
The company’s January 2026 announcement that the FDA cleared its Investigational New Drug application.
Life Biosciences: First Participant Dosed
The June 2026 announcement marking the start of dosing in the Phase 1 trial.
“Reprogramming to Recover Youthful Epigenetic Information and Restore Vision” — Nature
The 2020 mouse study reporting that OSK expression restored youthful epigenetic patterns, promoted nerve regeneration, and reversed vision loss.
The Sinclair Lab at Harvard Medical School
Research, publications, laboratory members, and information about David’s work on the biology of aging.
Lifespan: Why We Age—and Why We Don’t Have To
David Sinclair and Matthew LaPlante’s 2019 book about the biology of aging and emerging longevity research.
Lifespan
David’s longevity show, research magazine, community, and information about the Lifespan Foundation.
NMN Human-Trial Review — PubMed
A review of the safety evidence and proposed effects of nicotinamide mononucleotide in human clinical studies.
NMN and Physical Performance — PubMed
A systematic review examining randomized trials of NMN and physical-performance measurements.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Episode Description:
Prediction markets allow people to trade contracts tied to real-world events—from elections and weather to rocket launches, airport traffic, awards, and the words a public figure might use during a speech.
But James argues that having an opinion isn’t enough. Betting on your favorite team, preferred candidate, or a vague feeling about what might happen is speculation without an edge. His rule is simple: only participate when you believe you have an unfair advantage.
In this solo episode, James explains the two advantages he looks for. The first comes from understanding how prediction-market participants behave—especially their tendency to overlook outcomes that appear almost certain because the potential payout looks small. The second comes from researching a particular market more thoroughly than the other participants.
He walks through three trades he made: whether the U.S. government will confirm the existence of extraterrestrial life before 2027, whether SpaceX will exceed a specified number of June launches, and whether Donald Trump will use the phrase “movie star” during an upcoming speech. He also examines TSA passenger data to show why good research sometimes leads to the most important decision of all: not making the trade.
The larger lesson is not that any outcome is guaranteed. It is that a repeatable process—researching the data, comparing your estimated probability with the market price, diversifying, and walking away when the edge is unclear—is more useful than betting on instinct.

Editorial Note:
Prediction-market contracts are speculative and can result in the loss of the full amount committed to a position. Short-term returns expressed on an annualized basis are hypothetical comparisons, not guarantees that the same opportunity can be repeated throughout a year. This episode is educational and reflects James’s personal reasoning, not individualized financial advice.

What You’ll Learn:
How binary prediction-market contracts are priced and settled.
Why James avoids trades based only on personal preference or intuition.
The two types of informational advantage he looks for before entering a market.
Why apparently likely outcomes can still be priced below James’s estimate of their probability.
How to compare a contract’s price with your independent estimate of the outcome.
Why diversification matters when a single losing contract can erase several smaller gains.
How historical speeches, launch schedules, and public datasets can inform a trade.
Why declining to place a bet is often the correct conclusion when the evidence is inconclusive.

Timestamped Chapters:
[02:00] The Search for an Unfair Advantage
Why James believes a feeling or personal preference is not a sufficient reason to place a bet.
[02:43] What Is a Prediction Market?
How event contracts cover subjects ranging from weather and elections to entertainment, sports, and public speeches.
[03:29] How Yes-or-No Contracts Work
A hypothetical presidential contract illustrates pricing, payouts, and profit.
[04:26] Don’t Bet on What You Want to Happen
Why fandom, political preference, and intuition can distort judgment.
[05:12] Two Types of Informational Advantage
James distinguishes between understanding market behavior and possessing unusually strong research about one event.
[06:30] Why Traders May Overlook Near-Certainties
How small-looking payouts and the cost of tying up capital can leave heavily favored outcomes below full value.
[07:52] Will the Government Confirm That Aliens Exist?
James explains why he bought “No” contracts on an official confirmation occurring before 2027.
[10:40] Diversifying a Basket of High-Probability Trades
Why James prefers multiple positions rather than concentrating everything in one supposedly certain outcome.
[11:20] The SpaceX Launch Trade
Using completed launches, the remaining calendar, and an upcoming mission to evaluate a five-day contract.
[13:38] Turning Presidential Speeches Into Data
How James analyzes recurring words and phrases instead of relying on opinions about Donald Trump.
[15:38] Betting Against “Movie Star”
Why past speeches, synonyms, context, and the market price led James to take the “No” side.
[18:30] TSA Passenger Data—and Knowing When to Pass
Historical checkpoint volume offers useful evidence, but not necessarily enough of an edge to justify a trade.
[21:01] Three Trades and One Repeatable System
James reviews his positions and the difference between market-level and event-specific advantages.
[23:00] Prediction Markets as a Continuing Experiment
Why James plans to keep testing the approach and sharing shorter updates.

Additional Resources:
Kalshi: What Are Prediction Markets? — An introduction to event contracts, pricing, and settlement.
Kalshi: How Prices Are Determined — How opposing orders are matched and market prices are established.
Kalshi FAQ — Platform rules, prohibited conduct, trading mechanics, and account information.
CFTC: Understanding Prediction Markets and Event Contracts — The federal regulator’s overview of event contracts and their uses.
CFTC: Contracts and Products — Regulatory information about derivatives and event contracts.
TSA Checkpoint Travel Numbers — Official daily passenger-screening figures used for historical comparisons.
SpaceX Launches — Official information about completed and upcoming SpaceX missions.

See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.